Viiv Hlthcare Drug Patent Portfolio
Viiv Hlthcare owns 18 orange book drugs protected by 43 US patents with Rescriptor having the least patent protection, holding only 2 patents. And Juluca with maximum patent protection, holding 11 patents. Given below is the list of Viiv Hlthcare's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12011506 | Combination and uses and treatments thereof | 05 Sep, 2038 | Active |
| US11224597 | Pharmaceutical compositions | 15 Sep, 2031 | Active |
| US11234985 | Antiviral therapy | 24 Jan, 2031 | Active |
| US10426780 | Antiviral therapy | 24 Jan, 2031 | Active |
| US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | 08 Jun, 2030 | Active |
| US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | 08 Dec, 2029 | Active |
| US8168615 | Prodrugs of piperazine and substituted piperidine antiviral agents | 13 Jul, 2029 | Active |
| US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | 05 Apr, 2028 | Active |
| US7745625 | Prodrugs of piperazine and substituted piperidine antiviral agents | 19 Nov, 2027 | Active |
| US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | 05 Oct, 2027 | Active |
| US11389447 | Aqueous suspensions of TMC278 | 30 Jun, 2027 | Active |
| US10927129 | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity | 28 Apr, 2026 | Active |
| US8410103 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent | 28 Apr, 2026 | Active |
| US7125879 | HIV inhibiting pyrimidines derivatives | 21 Apr, 2025 | Active |
| US8461333 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | 25 Feb, 2025 | Active |
| US7368460 | Tropane derivatives useful in therapy | 25 May, 2023 | Expired |
| US8080551 | HIV inhibiting pyrimidines derivatives | 11 Apr, 2023 | Expired |
| US7368460 | Tropane derivatives useful in therapy | 25 Nov, 2022 | Expired |
| US8101629 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | 09 Aug, 2022 | Expired |
| US6667314 | Tropane derivatives useful in therapy | 06 Feb, 2022 | Expired |
| US7576097 | Tropane derivatives useful in therapy | 25 Nov, 2021 | Expired |
| US6667314 | Tropane derivatives useful in therapy | 06 Aug, 2021 | Expired |
| US7576097 | Tropane derivatives useful in therapy | 25 May, 2021 | Expired |
| US6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents | 26 Feb, 2021 | Expired |
| US6514953 | Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate | 15 Jan, 2020 | Expired |
| US7067522 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | 20 Dec, 2019 | Expired |
| US6586430 | CCR5 modulators | 01 Dec, 2019 | Expired |
| US6641843 | Pharmaceutical compositions | 04 Aug, 2019 | Expired |
| US6514953 | Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate | 15 Jul, 2019 | Expired |
| US6177101 | Delavirdine high strength tablet formulation | 07 Jun, 2019 | Expired |
| US6641843 | Pharmaceutical compositions | 04 Feb, 2019 | Expired |
| US6294540 | Carbocyclic nucleoside hemisulfate and its use in treating viral infections | 14 Nov, 2018 | Expired |
| US6004968 | Pharmaceutical compositions containing lamivudine | 20 Sep, 2018 | Expired |
| US6436989 | Prodrugs of aspartyl protease inhibitors | 24 Jun, 2018 | Expired |
| US6294540 | Carbocyclic nucleoside hemisulfate and its use in treating viral infections | 14 May, 2018 | Expired |
| US6004968 | Pharmaceutical compositions containing lamivudine | 20 Mar, 2018 | Expired |
| US6436989 | Prodrugs of aspartyl protease inhibitors | 24 Dec, 2017 | Expired |
| US5905082 | Crystalline oxathiolane derivatives | 18 Nov, 2016 | Expired |
| US6417191 | Synergistic combinations of zidovudine, 1592U89 and 3TC | 28 Sep, 2016 | Expired |
| US5905082 | Crystalline oxathiolane derivatives | 18 May, 2016 | Expired |
| US6417191 | Synergistic combinations of zidovudine, 1592U89 and 3TC | 28 Mar, 2016 | Expired |
| US5563142 | Diaromatic substituted compounds as anti-HIV-1 agents | 08 Oct, 2013 | Expired |
| US5859021 | Antiviral combinations | 15 Nov, 2012 | Expired |
Latest Legal Activities on Viiv Hlthcare's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Viiv Hlthcare.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 28 May, 2024 | US11389447 |
| Mail Patent eCofC Notification | 28 May, 2024 | US11389447 |
| Patent eCofC Notification | 28 May, 2024 | US11389447 |
| Recordation of Patent eCertificate of Correction | 28 May, 2024 | US11389447 |
|
Email Notification
Critical
| 23 Apr, 2024 | US11389447 |
| Mail Pub Notice re 312 amendment | 23 Apr, 2024 | US11389447 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 18 Apr, 2024 | US11389447 |
|
Patent Term Extension Certificate
Critical
| 11 Mar, 2024 | US8168615 |
| transaction for FDA Determination of Regulatory Review Period | 25 Jan, 2024 | US8410103 |
| transaction for FDA Determination of Regulatory Review Period | 25 Jan, 2024 | US8410103 |
|
Expire Patent
Critical
| 22 Jan, 2024 | US8080551 |
|
Expire Patent
Critical
| 22 Jan, 2024 | US8080551 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Oct, 2023 | US8168615 |
| Notice of Final Determination -Eligible | 03 Oct, 2023 | US8168615 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Aug, 2023 | US8129385 |
Viiv Hlthcare's Drug Patent Litigations
Viiv Hlthcare's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 18, 2012, against patent number US6436989. The petitioner Ranbaxy Laboratories Ltd. et al., challenged the validity of this patent, with Vertex Pharmaceuticals Incorporated as the respondent. Click below to track the latest information on how companies are challenging Viiv Hlthcare's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11389447 | October, 2020 |
Decision
(02 Aug, 2021)
| JANSSEN SCIENCES IRELAND UC | |
| US6436989 | February, 2016 |
FWD Entered
(28 Jul, 2017)
| Vertex Pharmaceuticals Incorporated | Lupin Limited |
| US6436989 | December, 2014 |
Terminated-Settled
(03 Nov, 2015)
| Vertex Pharmaceuticals Incorporated | Lupin Limited |
| US6417191 | June, 2014 |
Terminated-Settled
(03 Aug, 2015)
| ViiV Healthcare Co. | Apotex Corp. |
| US6417191 | January, 2015 |
Terminated-Denied
(25 Jun, 2015)
| ViiV Healthcare Co. | Teva Pharmaceuticals USA, Inc. |
| US6436989 | October, 2012 |
Terminated-Settled
(15 Nov, 2013)
| Vertex Pharmaceuticals Incorporated | Ranbaxy Laboratories Ltd. et al. |
Viiv Hlthcare Drug Patents' Oppositions Filed in EPO
Viiv Hlthcare drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 09, 2012, by Hamm, Volker. This opposition was filed on patent number EP05108086A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP17195280A | Feb, 2020 | Gilead Sciences, Inc. | Opposition rejected |
| EP16187411A | May, 2019 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP16187411A | May, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP16187411A | May, 2019 | Sandoz AG | Granted and Under Opposition |
| EP16187411A | May, 2019 | Cooke, Richard | Granted and Under Opposition |
| EP15164931A | Dec, 2018 | Cooke, Richard | Granted and Under Opposition |
| EP15164931A | Dec, 2018 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP16154531A | Dec, 2018 | Gilead Sciences, Inc. | Patent maintained as amended |
| EP07786802A | Oct, 2018 | HGF Limited | Opposition rejected |
| EP06822311A | Nov, 2016 | Zwicker Schnappauf & Partner PartG mbB | Opposition procedure closed |
| EP11737484A | Feb, 2016 | Page White & Farrer Limited | Revoked |
| EP11737484A | Feb, 2016 | LEK Pharmaceuticals d.d. | Revoked |
| EP11737484A | Feb, 2016 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Revoked |
| EP11737484A | Feb, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP04787096A | Jan, 2016 | Page White & Farrer Limited | Patent maintained as amended |
| EP06758843A | May, 2014 | Ahrens, Gabriele | Opposition procedure closed |
| EP05108086A | Feb, 2012 | Hamm, Volker | The patent has been limited |
Viiv Hlthcare's Family Patents
Viiv Hlthcare Drug List
Given below is the complete list of Viiv Hlthcare's drugs and the patents protecting them.
1. Apretude
Apretude is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11224597 | Pharmaceutical compositions |
15 Sep, 2031
(6 years from now)
| Active |
| US10927129 | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
28 Apr, 2026
(1 year, 6 months from now)
| Active |
| US8410103 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
28 Apr, 2026
(1 year, 6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Apretude's drug page
2. Cabenuva Kit
Cabenuva Kit is protected by 7 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11224597 | Pharmaceutical compositions |
15 Sep, 2031
(6 years from now)
| Active |
| US11389447 | Aqueous suspensions of TMC278 |
30 Jun, 2027
(2 years from now)
| Active |
| US10927129 | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
28 Apr, 2026
(1 year, 6 months from now)
| Active |
| US8410103 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
28 Apr, 2026
(1 year, 6 months from now)
| Active |
| US7125879 | HIV inhibiting pyrimidines derivatives |
21 Apr, 2025
(6 months from now)
| Active |
| US8080551 | HIV inhibiting pyrimidines derivatives |
11 Apr, 2023
(1 year, 6 months ago)
| Expired |
| US6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
26 Feb, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cabenuva Kit's drug page
3. Combivir
Combivir is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5905082
(Pediatric)
| Crystalline oxathiolane derivatives |
18 Nov, 2016
(7 years ago)
| Expired |
| US5905082 | Crystalline oxathiolane derivatives |
18 May, 2016
(8 years ago)
| Expired |
| US5859021
(Pediatric)
| Antiviral combinations |
15 Nov, 2012
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combivir's drug page
4. Dovato
Dovato is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11234985 | Antiviral therapy |
24 Jan, 2031
(6 years from now)
| Active |
| US9242986
(Pediatric)
| Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
08 Jun, 2030
(5 years from now)
| Active |
| US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
08 Dec, 2029
(5 years from now)
| Active |
| US8129385
(Pediatric)
| Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
05 Apr, 2028
(3 years from now)
| Active |
| US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
05 Oct, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dovato's drug page
5. Epivir
Epivir is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6004968
(Pediatric)
| Pharmaceutical compositions containing lamivudine |
20 Sep, 2018
(6 years ago)
| Expired |
| US6004968 | Pharmaceutical compositions containing lamivudine |
20 Mar, 2018
(6 years ago)
| Expired |
| US5905082
(Pediatric)
| Crystalline oxathiolane derivatives |
18 Nov, 2016
(7 years ago)
| Expired |
| US5905082 | Crystalline oxathiolane derivatives |
18 May, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epivir's drug page
Explore Our Curated Drug Screens
6. Epzicom
Epzicom is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6294540
(Pediatric)
| Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
14 Nov, 2018
(5 years ago)
| Expired |
| US6294540 | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
14 May, 2018
(6 years ago)
| Expired |
| US5905082
(Pediatric)
| Crystalline oxathiolane derivatives |
18 Nov, 2016
(7 years ago)
| Expired |
| US6417191
(Pediatric)
| Synergistic combinations of zidovudine, 1592U89 and 3TC |
28 Sep, 2016
(8 years ago)
| Expired |
| US5905082 | Crystalline oxathiolane derivatives |
18 May, 2016
(8 years ago)
| Expired |
| US6417191 | Synergistic combinations of zidovudine, 1592U89 and 3TC |
28 Mar, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epzicom's drug page
7. Juluca
Juluca is protected by 11 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12011506 | Combination and uses and treatments thereof |
05 Sep, 2038
(13 years from now)
| Active |
| US10426780 | Antiviral therapy |
24 Jan, 2031
(6 years from now)
| Active |
| US9242986
(Pediatric)
| Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
08 Jun, 2030
(5 years from now)
| Active |
| US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
08 Dec, 2029
(5 years from now)
| Active |
| US8129385
(Pediatric)
| Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
05 Apr, 2028
(3 years from now)
| Active |
| US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
05 Oct, 2027
(2 years from now)
| Active |
| US7125879 | HIV inhibiting pyrimidines derivatives |
21 Apr, 2025
(6 months from now)
| Active |
| US8080551 | HIV inhibiting pyrimidines derivatives |
11 Apr, 2023
(1 year, 6 months ago)
| Expired |
| US8101629 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
09 Aug, 2022
(2 years ago)
| Expired |
| US6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
26 Feb, 2021
(3 years ago)
| Expired |
| US7067522 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
20 Dec, 2019
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Juluca's drug page
8. Lexiva
Lexiva is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6514953
(Pediatric)
| Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate |
15 Jan, 2020
(4 years ago)
| Expired |
| US6514953 | Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate |
15 Jul, 2019
(5 years ago)
| Expired |
| US6436989
(Pediatric)
| Prodrugs of aspartyl protease inhibitors |
24 Jun, 2018
(6 years ago)
| Expired |
| US6436989 | Prodrugs of aspartyl protease inhibitors |
24 Dec, 2017
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lexiva's drug page
9. Rescriptor
Rescriptor is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6177101 | Delavirdine high strength tablet formulation |
07 Jun, 2019
(5 years ago)
| Expired |
| US5563142 | Diaromatic substituted compounds as anti-HIV-1 agents |
08 Oct, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rescriptor's drug page
10. Rukobia
Rukobia is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8168615 | Prodrugs of piperazine and substituted piperidine antiviral agents |
13 Jul, 2029
(4 years from now)
| Active |
| US7745625 | Prodrugs of piperazine and substituted piperidine antiviral agents |
19 Nov, 2027
(3 years from now)
| Active |
| US8461333 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents |
25 Feb, 2025
(4 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rukobia's drug page
11. Selzentry
Selzentry is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7368460
(Pediatric)
| Tropane derivatives useful in therapy |
25 May, 2023
(1 year, 4 months ago)
| Expired |
| US7368460 | Tropane derivatives useful in therapy |
25 Nov, 2022
(1 year, 10 months ago)
| Expired |
| US6667314
(Pediatric)
| Tropane derivatives useful in therapy |
06 Feb, 2022
(2 years ago)
| Expired |
| US7576097
(Pediatric)
| Tropane derivatives useful in therapy |
25 Nov, 2021
(2 years ago)
| Expired |
| US6667314 | Tropane derivatives useful in therapy |
06 Aug, 2021
(3 years ago)
| Expired |
| US7576097 | Tropane derivatives useful in therapy |
25 May, 2021
(3 years ago)
| Expired |
| US6586430 | CCR5 modulators |
01 Dec, 2019
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Selzentry's drug page
12. Tivicay
Tivicay is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9242986
(Pediatric)
| Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
08 Jun, 2030
(5 years from now)
| Active |
| US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
08 Dec, 2029
(5 years from now)
| Active |
| US8129385
(Pediatric)
| Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
05 Apr, 2028
(3 years from now)
| Active |
| US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
05 Oct, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tivicay's drug page
13. Tivicay Pd
Tivicay Pd is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9242986
(Pediatric)
| Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
08 Jun, 2030
(5 years from now)
| Active |
| US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
08 Dec, 2029
(5 years from now)
| Active |
| US8129385
(Pediatric)
| Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
05 Apr, 2028
(3 years from now)
| Active |
| US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
05 Oct, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tivicay Pd's drug page
14. Triumeq
Triumeq is protected by 10 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9242986
(Pediatric)
| Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
08 Jun, 2030
(5 years from now)
| Active |
| US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
08 Dec, 2029
(5 years from now)
| Active |
| US8129385
(Pediatric)
| Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
05 Apr, 2028
(3 years from now)
| Active |
| US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
05 Oct, 2027
(2 years from now)
| Active |
| US6294540
(Pediatric)
| Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
14 Nov, 2018
(5 years ago)
| Expired |
| US6294540 | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
14 May, 2018
(6 years ago)
| Expired |
| US5905082
(Pediatric)
| Crystalline oxathiolane derivatives |
18 Nov, 2016
(7 years ago)
| Expired |
| US6417191
(Pediatric)
| Synergistic combinations of zidovudine, 1592U89 and 3TC |
28 Sep, 2016
(8 years ago)
| Expired |
| US5905082 | Crystalline oxathiolane derivatives |
18 May, 2016
(8 years ago)
| Expired |
| US6417191 | Synergistic combinations of zidovudine, 1592U89 and 3TC |
28 Mar, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Triumeq's drug page
15. Triumeq Pd
Triumeq Pd is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9242986
(Pediatric)
| Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
08 Jun, 2030
(5 years from now)
| Active |
| US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
08 Dec, 2029
(5 years from now)
| Active |
| US8129385
(Pediatric)
| Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
05 Apr, 2028
(3 years from now)
| Active |
| US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
05 Oct, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Triumeq Pd's drug page
16. Trizivir
Trizivir is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6294540
(Pediatric)
| Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
14 Nov, 2018
(5 years ago)
| Expired |
| US6294540 | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
14 May, 2018
(6 years ago)
| Expired |
| US5905082
(Pediatric)
| Crystalline oxathiolane derivatives |
18 Nov, 2016
(7 years ago)
| Expired |
| US6417191
(Pediatric)
| Synergistic combinations of zidovudine, 1592U89 and 3TC |
28 Sep, 2016
(8 years ago)
| Expired |
| US5905082 | Crystalline oxathiolane derivatives |
18 May, 2016
(8 years ago)
| Expired |
| US6417191 | Synergistic combinations of zidovudine, 1592U89 and 3TC |
28 Mar, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trizivir's drug page
17. Vocabria
Vocabria is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10927129 | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
28 Apr, 2026
(1 year, 6 months from now)
| Active |
| US8410103 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
28 Apr, 2026
(1 year, 6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vocabria's drug page
18. Ziagen
Ziagen is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6641843
(Pediatric)
| Pharmaceutical compositions |
04 Aug, 2019
(5 years ago)
| Expired |
| US6641843 | Pharmaceutical compositions |
04 Feb, 2019
(5 years ago)
| Expired |
| US6294540
(Pediatric)
| Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
14 Nov, 2018
(5 years ago)
| Expired |
| US6294540 | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
14 May, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ziagen's drug page